BACKGROUND & AIMS: The Notch signaling pathway is required for the expansion of undifferentiated pancreatic progenitor cells during embryonic development and has been implicated in the progression of pancreatic ductal adenocarcinoma (PDAC). The interaction of Notch ligands with their receptors promotes a gamma-secretase-dependent cleavage of the Notch receptor and release of the Notch intracellular domain, which translocates to the nucleus and activates transcription. We investigated the role of this pathway in PDAC progression. METHODS: We tested the effects of a gamma-secretase inhibitor (GSI) that blocks Notch signaling in PDAC cell lines and a genetically engineered mouse model of PDAC (Kras p53 L/+ mice). RESULTS: Notch signaling was activated in PDAC precursors and advanced tumors. The GSI inhibited the growth of premalignant pancreatic duct-derived cells in a Notch-dependent manner. Additionally, in a panel of over 400 human solid tumor-derived cell lines, PDAC cells, as a group, were more sensitive to the GSI than any other tumor type. Finally, the GSI completely inhibited tumor development in the genetically engineered model of invasive PDAC (P < .005, chi2 test; compared with mice exposed to vehicle). CONCLUSIONS: These results suggest that Notch signaling is required for PDAC progression. Pharmacologic targeting of this pathway offers therapeutic potential in this treatment-refractory malignancy.
BACKGROUND & AIMS: The Notch signaling pathway is required for the expansion of undifferentiated pancreatic progenitor cells during embryonic development and has been implicated in the progression of pancreatic ductal adenocarcinoma (PDAC). The interaction of Notch ligands with their receptors promotes a gamma-secretase-dependent cleavage of the Notch receptor and release of the Notch intracellular domain, which translocates to the nucleus and activates transcription. We investigated the role of this pathway in PDAC progression. METHODS: We tested the effects of a gamma-secretase inhibitor (GSI) that blocks Notch signaling in PDAC cell lines and a genetically engineered mouse model of PDAC (Krasp53 L/+ mice). RESULTS: Notch signaling was activated in PDAC precursors and advanced tumors. The GSI inhibited the growth of premalignant pancreatic duct-derived cells in a Notch-dependent manner. Additionally, in a panel of over 400 humansolid tumor-derived cell lines, PDAC cells, as a group, were more sensitive to the GSI than any other tumor type. Finally, the GSI completely inhibited tumor development in the genetically engineered model of invasive PDAC (P < .005, chi2 test; compared with mice exposed to vehicle). CONCLUSIONS: These results suggest that Notch signaling is required for PDAC progression. Pharmacologic targeting of this pathway offers therapeutic potential in this treatment-refractory malignancy.
Authors: Andrew W Duncan; Frédérique M Rattis; Leah N DiMascio; Kendra L Congdon; Gregory Pazianos; Chen Zhao; Keejung Yoon; J Michael Cook; Karl Willert; Nicholas Gaiano; Tannishtha Reya Journal: Nat Immunol Date: 2005-01-23 Impact factor: 25.606
Authors: Johan H van Es; Marielle E van Gijn; Orbicia Riccio; Maaike van den Born; Marc Vooijs; Harry Begthel; Miranda Cozijnsen; Sylvie Robine; Doug J Winton; Freddy Radtke; Hans Clevers Journal: Nature Date: 2005-06-16 Impact factor: 49.962
Authors: Jan Nygaard Jensen; Erin Cameron; Maria Veronica R Garay; Thomas W Starkey; Roberto Gianani; Jan Jensen Journal: Gastroenterology Date: 2005-03 Impact factor: 22.682
Authors: Tim Sparey; Dirk Beher; Jonathan Best; Mirlinda Biba; José L Castro; Earl Clarke; Joanne Hannam; Timothy Harrison; Huw Lewis; Andrew Madin; Mark Shearman; Bindi Sohal; Nancy Tsou; Christopher Welch; Jonathan Wrigley Journal: Bioorg Med Chem Lett Date: 2005-10-01 Impact factor: 2.823
Authors: A Apelqvist; H Li; L Sommer; P Beatus; D J Anderson; T Honjo; M Hrabe de Angelis; U Lendahl; H Edlund Journal: Nature Date: 1999-08-26 Impact factor: 49.962
Authors: Anna L Means; Ingrid M Meszoely; Kazufumi Suzuki; Yoshiharu Miyamoto; Anil K Rustgi; Robert J Coffey; Christopher V E Wright; Doris A Stoffers; Steven D Leach Journal: Development Date: 2005-07-14 Impact factor: 6.868
Authors: Sripathi M Sureban; Randal May; Stan A Lightfoot; Aimee B Hoskins; Megan Lerner; Daniel J Brackett; Russell G Postier; Rama Ramanujam; Altaf Mohammed; Chinthalapally V Rao; James H Wyche; Shrikant Anant; Courtney W Houchen Journal: Cancer Res Date: 2011-02-01 Impact factor: 12.701
Authors: Vindhya Palagani; Mona El Khatib; Uta Kossatz; Przemyslaw Bozko; Martin R Müller; Michael P Manns; Till Krech; Nisar P Malek; Ruben R Plentz Journal: PLoS One Date: 2012-10-19 Impact factor: 3.240
Authors: J Tammam; C Ware; C Efferson; J O'Neil; S Rao; X Qu; J Gorenstein; M Angagaw; H Kim; C Kenific; K Kunii; K J Leach; G Nikov; J Zhao; X Dai; J Hardwick; M Scott; C Winter; L Bristow; C Elbi; J F Reilly; T Look; G Draetta; Lht Van der Ploeg; N E Kohl; P R Strack; P K Majumder Journal: Br J Pharmacol Date: 2009-09-23 Impact factor: 8.739